Skip to main content
SpringerLink
Log in
Book cover

Is Crohn’s Disease a Mycobacterial Disease? pp 54–63Cite as

Immunotherapeutical Approaches to Crohn’s Disease in View of a Possible Pathogenic Role of Mycobacterial Antigens

  • Chapter

  • 49 Accesses

Part of the book series: Developments in Gastroenterology ((DIGA,volume 14))

Abstract

The immune system of the intestinal tract has been extensively studied. The lamina propria of adults is heavy populated with a variety of lymphoid cells: B- and T-lymphocytes, plasma cells, macrophages, mast cells, eosinophils and basophils. In normal subjects the majority of the B-cells are committed to IgA synthesis (90%), the residual 10% being represented (in order of decreasing frequency) by IgM, IgG, IgE and IgD producing plasma cells. These cells, which are located diffusely in the mucosa and more organized in Peyer’s patches, together with the an intact mucosal layer provide an effective barrier to the antigenic food load, that passes the bowel daily. Small amounts of antigen can transmigrate through the mucosa either by endo/pinocytic processes or via the tight junction complex. The production of antibodies to antigens penetrating the barrier is a physiological process that usually results in systemic tolerance. Changes in these immunological processes, caused by an altered mucosal barrier, an abnormal antigen-antibody or antigen-antigen presenting cell response, may play a role in the pathogenesis of Crohn’s disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gas- troenterology 1989;97:927–31.

    CAS  Google Scholar 

  2. Howden CW, Robertson C, Ducan A, Morris AJ, Russel RI. Comparison of different measurements of intestinal permeability in inflammatory bowel disease. Am J Gastroenterol 1991;86:1445–9.

    PubMed  CAS  Google Scholar 

  3. Madara JL, Moore R, Carlson S. Alteration of intestinal tight junction structure and permeability by cytoskeletal contraction. Am Phy Soc 1987;C854–61.

    Google Scholar 

  4. Ouyang Q, El-Youssef M, Yen-Lieberman B, Sapatnekar W, Youngman KR, Kusugami K, et al. Expression of HLA-DR antigens in inflammatory bowel disease mucosa: Role of intestinal lamina propria mononuclear cell-derived interferon T. Dig Dis Sci 1988;33:1528–36.

    Article  Google Scholar 

  5. Cuvelier C, Mielants H, Vos de M, Veys E, Roels H. Major histocompatibility complex class II antigen (HLA-DR) expression by ileal epithelial cells in patients with seronegative spondylarthropathy. Gut 1990;31:545–9.

    Article  PubMed  CAS  Google Scholar 

  6. Mayer L, Eisenhardt D, Salomon P, Bauer W, Pious R, Piccinini L. Expression of class II molecules on intestinal epithelial cells in humans. Differences between normal and inflammatory bowel diseases. Gastroenterology 1991;100:3–12.

    PubMed  CAS  Google Scholar 

  7. James SP, Fiocchi C, Greaff AS, Strober W. Phenotypic analysis of lamina propria lymphocytes. Predominance of helper-inducer and cytolytic T-cell phenotypes and deficiency of suppressor-inducer phenotypes in Crohn’s disease and controle patients. Gastroenterology 1986;91:1483–9.

    PubMed  CAS  Google Scholar 

  8. Rappaport H, Burgoyne FH, Smetana HF. The pathology of regional enteritis. Milit Surg 1951;109:463–502

    CAS  Google Scholar 

  9. Zifronini A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured .intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983;24:659–65.

    Article  Google Scholar 

  10. Ferguson A. Why study T cell subsets in Crohn’s disease? Gut 1983;24:687–91.

    Article  PubMed  CAS  Google Scholar 

  11. Selby WS, Janossy G, Bofill M, Jewell DP. Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques. Gut 1984;25:32–40.

    Article  PubMed  CAS  Google Scholar 

  12. Konttinen YT, Bergroth V, Nordstrom D, Segerberg-Konttinen M, Seppala K, Salaspuro M. Lymphocyte activation in vivo in the intestinal mucosa of patients with Crohn’s disease. J Clin Lab Immunol 1987;22:59–63.

    PubMed  CAS  Google Scholar 

  13. Fais S, Pallone F, Squarcia O, et al. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: 1. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin Exp Immunol 1987;68:605–12.

    PubMed  CAS  Google Scholar 

  14. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boivirant M. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn’s disease. In vivo state of activation and in vitro response to stimulation as defined by expression of early activation antigens. Gut 1987;28:745–53.

    Article  PubMed  CAS  Google Scholar 

  15. Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn’s disease and ulcerative colitis. Gut 1990;31:1365–70.

    Article  PubMed  CAS  Google Scholar 

  16. Monk TJ, Spencer J, Cerf-Bensussan N, MacDonald TT. Activation of mucosal T-cells in situ with anti-CD3 antibody: phenotype of activated T-cells and their distribution within the mucosal micro-environment. Clin Exp Immunol 1988;74:216–22.

    PubMed  CAS  Google Scholar 

  17. Brynskov J, Tvede N, Andersen CB, Vilien M. Increased concentrations of interleukin lß,, interleukin-2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992;33:55–58.

    Article  PubMed  CAS  Google Scholar 

  18. Meuler CH, Knoflach P, Zielinski CC. T-cell activation in Crohn’s disease. Gastroenterology 1990;98:639–46.

    Google Scholar 

  19. Crabtree JE, Juby LD, Heatley RV, Lobo AJ, Bullimore DW, Axon ATR. Soluble interleukin-2 receptor in Crohn’s disease: relation of serum concentrations to disease activity. Gut 1990;31:1033–6.

    Article  PubMed  CAS  Google Scholar 

  20. Mahida YR, Callager A, Kurlak L, Hawkey CY. Plasma and tissue interleukin-2 receptor level in IBD. Clin Exp Immunol 1990;82:75–80.

    Article  PubMed  CAS  Google Scholar 

  21. Senju M, Hulstaert F, Lowder J, Jewell DP. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn’s disease. Gut 1991;32:779–83.

    Article  PubMed  CAS  Google Scholar 

  22. Cher DJ, Mosman TR. Two types of murine T cell clone. II. Delayed type hypersensitivity is mediated by Thl clones. J Immunol 1987;138:3688–94.

    PubMed  CAS  Google Scholar 

  23. Ashwell DJ, Fox BS, Schwartz RH. T cell recognition of antigen and Ia molecules involves a trimolecular complex, in Processing and presentation of antigens 1988;Academic Press, Inc London

    Google Scholar 

  24. Stewart-Tull DES. Immunologically important constituents of mycobacteria: adjuvants, in Biology of Mycobacteria Vol 2.1983 Academic Press London. IBSN 0-12-582302-9.

    Google Scholar 

  25. Blaauwgeers JL, Das PK, Slob AW, Houthoff HJ. Human gut wall reactivity to monoclonal antibodies against M. avium glycolipid in relation to Crohn’s disease (preliminary results). Acta Leprol (Geneve) 1989;7 Suppl 1:138–40.

    Google Scholar 

  26. Thayer WR Jr, Coutu JA, Chiodini RJ, Van Kruiningen HJ, Merkal RS. Possible role of mycobacteria in inflammatory bowel disease. II. Mycobacterial antibodies in Crohn’s disease. Dig Dis Sci 1984;29:1080–5.

    Article  PubMed  Google Scholar 

  27. Haanen JBAG, Waal de Malefijt R, Res PCM, Kraakman EM, Ottenhof THM, Vries RRP, et al. Selection of a human T helper type l-like T cell subset by mycobacteria. J Exp Med 1991;174:583–92.

    Article  PubMed  CAS  Google Scholar 

  28. Ebert EC, Bhatt BD, Lui S, Das KM. Induction of suppressor cells by Mycobacterium paratuberculosis antigen in inflammatory bowel disease. Cli Exp Immunol 1991;83:320–5.

    Article  CAS  Google Scholar 

  29. Atalla L, Linker-Israeli M, Steinman L, Rao NA. Inhibition of autoimmune uveitis by Anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990;31:1264–70.

    PubMed  CAS  Google Scholar 

  30. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosos patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurol 1986;36:777–84.

    Article  CAS  Google Scholar 

  31. Ortho Multicenter Transplantation Group. N Eng J Med 1985;313:337–42.

    Article  Google Scholar 

  32. Ziegler EJ,. N Eng J Med 1991;324:429-

    Article  CAS  Google Scholar 

  33. Catane R, Longo DL. Isr J Med Sci 1988;24:471–.

    PubMed  CAS  Google Scholar 

  34. O’Brien JJ, Bayless TM, Bayless JA. Use of Azathioprine or 6-Mercaptopurine in treatment of Crohn’s disease. Gastroenterology 1991;101:39–46.

    PubMed  Google Scholar 

  35. Hess AD, Colombani PM. Cyclosporin: mechanism of action: in vitro studies. Prog Allergy 1986;38:198–221.

    PubMed  CAS  Google Scholar 

  36. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Schaffalitzky de Muckadell O, Williams N, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N Engl J Med 1989;321:845–50

    Article  PubMed  CAS  Google Scholar 

  37. Alters SE, Sakai K, Steinman L, Oi VT. Mechanisms of anti-CD-mediated depletion and immunotherapy. A study using a set of chimeric anti-CD4 antibodies. J Immunol 1990;144:4587–92.

    PubMed  CAS  Google Scholar 

  38. James SP. Remission of Crohn’s disease after human immunodeficiency virus infection. Gastroenterology 1988;95:1667–9.

    PubMed  CAS  Google Scholar 

  39. Herzog C, Walker C, Miiller W, Rieber P, Reiter CRietmtiller G, et al. Anti-CD4 antibody treatment of patients with Rheumatoid arthritis: I. Effect on clinical course and circulating T Cells. J Autoimmunity 1998;2:627–42

    Article  Google Scholar 

  40. Walker C, Herzog C, Rieber P, Rietmuller G, Muller W, Pichler WJ. Anti-CD4 antibody treatment of patients with reumatoid arthritis: II. Effect of in vivo treatment on in vitro proliverative response of CD4 cells. J Autoimmun 1989;2:643–9.

    Article  PubMed  CAS  Google Scholar 

  41. Asano M, Minagawa T, Ohamichi M, Hiraga Y. Detection of endogenous cytokines in sera or lymph nodes obtained from patients with sarcoidosis. Clin Exp Immunol 1991:84:92–6.

    Article  PubMed  CAS  Google Scholar 

  42. Ruco LP; Stoppacciaro A; Pomponi D; Boraschi D; Santoni A; Tagliabue A; Uccini S; Baroni CD. Immunoreactivity for IL-1 beta and TNF alpha in human lymphoid and nonlymphoid tissues. Am J Pathol 1989;135:889–97.

    PubMed  CAS  Google Scholar 

  43. Dunn CJ, Hardee MM, Staite ND. Acute and chronic inflammatory responses to local administration of recombinant IL-1 alpha, IL-beta, TNF alpha, IL-2 and Ifn gamma in mice. Agents Actions 1989;27:290–3.

    Article  PubMed  CAS  Google Scholar 

  44. Kindler V, Sappino AP, Grau G, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731–40.

    Article  PubMed  CAS  Google Scholar 

  45. MacDonald TT, Hutchings P, Choy M-Y, Murch S, Cooke A. Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Cli Exp Immunol 1990;81:301–5.

    Article  CAS  Google Scholar 

  46. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89–91.

    Article  PubMed  CAS  Google Scholar 

  47. Exley AR, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock. Lancet 1990;335:1275–7.

    Article  PubMed  CAS  Google Scholar 

  48. Schönharting MM, Schade UF. The effect of pentoxyfilline in septic shock - new pharmacological aspects of an established drug. J Med 1989;20:97–105.

    PubMed  Google Scholar 

  49. Schade UF. Pentoxyfylline increases survival in murine endotoxine shock and decreases formation of tumor necrosis factor.Circ Shock 1990;31:171–81.

    PubMed  CAS  Google Scholar 

  50. Strieter RM, Remick DG, Ward PA et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxyfilline. Biochem Biophys Res Comm 1988;155:1230–6.

    Article  PubMed  CAS  Google Scholar 

  51. Sullivan GW, Carper HT, Novick WJ, Mandell GL. Inhibition of inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by Pentoxifylline. Infect Immun 1988;56:1722–9

    PubMed  CAS  Google Scholar 

  52. Sampaio EP, Sarno EN, Galilly R, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699–703

    Article  PubMed  CAS  Google Scholar 

  53. Mahida YR, Wu K, Jewel DP. Enhanced production of interleukin 1-ß by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn’s disease. Gut 1989;30:835–8.

    Article  PubMed  CAS  Google Scholar 

  54. Kusugami K, Youngman KR, West GA, Fiocchi C. Intestinal immune reactivity to interleukin 2 differs among Crohn’s disease, ulcerative colitis, and controls. Gastroenterology 1989;97:1–9.

    PubMed  CAS  Google Scholar 

  55. Mathew RC, Ragheb S, Boros DL. Recombinant IL-2 therapy reverses diminished granulomatous responsiveness in anti-L3T4-treated, Schistosoma mansoni-infected mice. J Immunol 1990;144:4356–61.

    PubMed  CAS  Google Scholar 

  56. Peyronnet P, Le Mauff B, Hourmant M, Cantarovich D, Dudigeon P, Olive D, et al. Prophylactic treatment of human kidney allograft recipients with a monoclonal antibody (33B3.1) directed against interleukin 2 receptor. Transplantation Procedings 1988;20:300–2.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. Gastroenterology, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands

    Arnold Stronkhorst, Guido N. J. Tytgat & Sander J. H. van Deventer

Authors
  1. Arnold Stronkhorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guido N. J. Tytgat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sander J. H. van Deventer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hepato-gastroenterology, Rijnstate Hospital, Arnhem, The Netherlands

    Chris J. J. Mulder

  2. Department of Hepato-gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands

    Guido N. J. Tytgat

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Stronkhorst, A., Tytgat, G.N.J., van Deventer, S.J.H. (1992). Immunotherapeutical Approaches to Crohn’s Disease in View of a Possible Pathogenic Role of Mycobacterial Antigens. In: Mulder, C.J.J., Tytgat, G.N.J. (eds) Is Crohn’s Disease a Mycobacterial Disease?. Developments in Gastroenterology, vol 14. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1830-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1830-9_7

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4808-8

  • Online ISBN: 978-94-011-1830-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation